RxDoctor Payments Data

Robert Piana, MD

Cardiovascular Disease · Nashville, TNNPI 1629068556

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $11,750 of the $16,349 with a category attached, or 71.9%. Abbott accounts for 71.9% of it on its own, with 6 other manufacturers making up the rest.

$16,349in general payments, 2019–2025

Across 51 payments — averaging $320.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$12K
  • Edwards Lifesciences$3K
  • Abiomed$565
  • Teleflex LLC$425
  • Boston Scientific$281
  • Medtronic$169
  • plus $161 from 1 others
$67,698in research payments, 2019–2025

Across 34 payments — averaging $1991.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • W. L. Gore & Associates, Inc.$67K
  • Abbott$250

What the payments were for

  • Consulting fees$11,75072%
  • Travel & lodging$1,75411%
  • Food & beverage$2,84517%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,349 in reported general payments places this provider in the 85th percentile of 429 cardiovascular disease providers in Tennessee.

See all cardiovascular disease providers in Tennessee

Medicare billing

Part B allowed, 2024
$127,814
Medicare patients
442
Services billed
1,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban85$128,480
Repatha SureclickEvolocumab121$107,177
EntrestoSacubitril/Valsartan47$72,245
XareltoRivaroxaban36$38,297
JardianceEmpagliflozin16$23,575
Ranolazine ErRanolazine22$2,173
Atorvastatin Calcium193$1,720
Metoprolol Succinate102$1,151
ClopidogrelClopidogrel Bisulfate93$955
Potassium Chloride37$917
Rosuvastatin Calcium86$835
Isosorbide Mononitrate ErIsosorbide Mononitrate51$772
Ezetimibe42$698
Prasugrel Hcl17$664
Amlodipine Besylate77$645

Paid to pharmacies, not to this prescriber.

Other cardiovascular disease in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →